First Time Loading...

Yipinhong Pharmaceutical Co Ltd
SZSE:300723

Watchlist Manager
Yipinhong Pharmaceutical Co Ltd Logo
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Watchlist
Price: 21.96 CNY -1.61% Market Closed
Updated: May 22, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

4.4B
+1%
Assets
Growth Rates:
1 Year
+7%
3 Years
+105%
5 Years
+147%
7 Years
-
10 Years
-
1.9B
+8%
Liabilities
Growth Rates:
1 Year
-8%
3 Years
+185%
5 Years
+290%
7 Years
-
10 Years
-
2.5B
-3%
Equity
Growth Rates:
1 Year
+23%
3 Years
+70%
5 Years
+94%
7 Years
-
10 Years
-

Balance Sheet Decomposition
Yipinhong Pharmaceutical Co Ltd

4.4B
Assets
1.9B
Liabilities
4.4B
Assets
1.9B
Liabilities
Current Assets 1.4B
Cash & Short-Term Investments 449m
Receivables 519.5m
Other Current Assets 391.4m
Non-Current Assets 3B
Long-Term Investments 637.5m
PP&E 1.8B
Intangibles 458.1m
Other Non-Current Assets 110.4m
Current Liabilities 1.5B
Accounts Payable 202.4m
Accrued Liabilities 128.2m
Short-Term Debt 714m
Other Current Liabilities 444.5m
Non-Current Liabilities 394.2m
Long-Term Debt 186m
Other Non-Current Liabilities 208.2m

Balance Sheet
Yipinhong Pharmaceutical Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
37
30
94
85
752
705
690
764
431
408
Cash
0
0
3
0
0
0
0
764
431
408
Cash Equivalents
37
30
91
85
752
705
690
0
0
0
Short-Term Investments
0
0
0
0
0
50
13
15
72
41
Total Receivables
236
112
152
182
342
331
319
329
442
519
Accounts Receivables
40
75
114
125
266
167
164
203
248
361
Other Receivables
196
38
37
57
76
163
156
126
194
158
Inventory
76
109
100
134
78
82
110
115
178
346
Other Current Assets
38
27
60
739
47
11
77
340
288
45
Total Current Assets
387
278
405
1 140
1 218
1 178
1 209
1 564
1 411
1 360
PP&E Net
190
185
173
178
198
290
556
1 184
1 719
1 839
PP&E Gross
0
0
173
178
198
290
556
1 184
1 719
1 839
Accumulated Depreciation
0
0
68
85
106
129
155
198
253
378
Intangible Assets
155
165
172
160
349
313
298
460
461
447
Goodwill
0
0
0
0
0
0
0
11
11
11
Long-Term Investments
0
0
0
0
0
0
38
414
389
638
Other Long-Term Assets
2
2
2
4
16
13
44
95
107
110
Other Assets
0
0
0
0
0
0
0
11
11
11
Total Assets
734
N/A
631
-14%
752
+19%
1 482
+97%
1 781
+20%
1 795
+1%
2 145
+20%
3 728
+74%
4 098
+10%
4 405
+7%
Liabilities
Accounts Payable
48
16
13
12
19
20
56
41
69
202
Accrued Liabilities
4
7
27
30
38
43
54
75
92
128
Short-Term Debt
108
61
32
2
142
199
293
949
725
714
Current Portion of Long-Term Debt
0
0
0
0
139
0
0
25
28
66
Other Current Liabilities
146
46
51
61
85
122
154
117
295
378
Total Current Liabilities
306
130
123
104
423
384
557
1 206
1 209
1 489
Long-Term Debt
300
296
291
251
0
0
0
353
590
186
Deferred Income Tax
0
0
0
0
0
0
0
67
58
49
Minority Interest
0
5
3
1
1
12
10
144
115
76
Other Liabilities
0
4
2
19
59
70
93
84
76
83
Total Liabilities
606
N/A
435
-28%
419
-4%
375
-11%
483
+29%
466
-3%
660
+42%
1 854
+181%
2 047
+10%
1 883
-8%
Equity
Common Stock
90
120
120
160
162
161
161
288
288
454
Retained Earnings
34
23
160
317
501
613
807
1 075
1 309
1 437
Additional Paid In Capital
4
53
53
630
669
667
653
571
542
814
Treasury Stock
0
0
0
0
33
112
136
169
193
183
Other Equity
0
0
0
0
0
0
0
110
105
0
Total Equity
128
N/A
196
+54%
333
+70%
1 107
+232%
1 298
+17%
1 329
+2%
1 485
+12%
1 874
+26%
2 051
+9%
2 522
+23%
Total Liabilities & Equity
734
N/A
631
-14%
752
+19%
1 482
+97%
1 781
+20%
1 795
+1%
2 145
+20%
3 728
+74%
4 098
+10%
4 405
+7%
Shares Outstanding
Common Shares Outstanding
162
216
216
288
291
284
282
420
420
442

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 139,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.